Watch These Hot Ones: Dick’s Sporting Goods (NYSE:DKS), Amgen (NASDAQ:AMGN), Companhia Energetica Minas Gerais (NYSE:CIG), Puma Biotechnology (NYSE:PBYI)

Owens Corning (NYSE:OC) shares moved down -4.12% in last trading session and ended the day at $41.23. OC Gross Margin is 20.60% and its has a return on assets of 3.30%. Owens Corning (NYSE:OC) quarterly performance is -10.28%.

On 10 February, Owens Corning (NYSE:OC) reported consolidated net sales of $5.4 billion in 2015, compared to net sales of $5.3 billion in 2014. Fourth-quarter 2015 adjusted earnings were $79 million, or $0.66 per diluted share, compared with $55 million, or $0.47 per diluted share, during the same period one year ago.

Dick’s Sporting Goods Inc. (NYSE:DKS) ended the last trading day at $36.57. Company weekly volatility is calculated as 2.95% and price to cash ratio as 56.98. Dick’s Sporting Goods Inc. (NYSE:DKS) showed a weekly performance of -6.18%.

On 5 February, Dick’s Sporting Goods Inc. (NYSE:DKS) announced it is offering UberRUSH as a way to provide displaced fans in Chicago and New York City with the chance to be part of their team’s championship celebration immediately following Sunday’s game.

Amgen Inc. (NASDAQ:AMGN) caters to the Healthcare space. It has a net profit margin of 32.00% and weekly performance is -5.64%. On the last day of trading company shares ended up at $141.46. Amgen Inc. (NASDAQ:AMGN) distance from 50-day simple moving average (SMA50) is 21.74%.

On 9 February, Amgen Inc. (NASDAQ:AMGN) and biochemist Bruce Alberts are starting a new journal, F1000Research, aimed to address this problem with an open access online source.

Companhia Energetica Minas Gerais (ADR) (NYSE:CIG) shares moved down -15.06% in last trading session and ended the day at $1.41. CIG Gross Margin is 29.90% and its has a return on assets of 9.10%. Companhia Energetica Minas Gerais (ADR) (NYSE:CIG) quarterly performance is -29.12%.

Companhia Energetica Minas Gerais (ADR) (NYSE:CIG) is Downgraded by RBC Capital Mkts to ” Sector Perform” while Lowering the Price Target of the company shares to $ 47 from a previous price target of $5.

Puma Biotechnology, Inc. (NYSE:PBYI) caters to the Healthcare space. Its performance is -12.03%. On the last day of trading company shares ended up at $38.69. Puma Biotechnology, Inc. (NYSE:PBYI) distance from 50-day simple moving average (SMA50) is -36.67%.

On 11 February, Puma Biotechnology, Inc. (NYSE:PBYI) announced that results from the ExteNET Phase III clinical trial of neratinib in patients with early stage HER2 positive breast cancer were published in the journal The Lancet Oncology. The article entitled “Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET); a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial” appears in the February 10, 2016 online issue and will be published in a future print issue of the journal.